Opportunity Information: Apply for RFA DA 19 022
The Mobile Technologies Extending Reach of Primary Care for Substance-Use-Disorders (R41/R42 Clinical Trial Optional) opportunity (Funding Opportunity Number RFA-DA-19-022) is a National Institutes of Health (NIH) small business grant focused on creating and testing a prototype mobile or tablet application that can be used in U.S. primary care settings to support follow-up care for patients with risky or problematic substance use. The core idea is to give primary care providers a practical, low-cost, and easy-to-use digital tool that helps them extend the impact of brief interventions beyond the clinic visit, especially when time, staffing, and access to specialty treatment are limited.
A central requirement is that the application deliver timely, tailored feedback to patients after they have received an intervention for risky substance use. The tailoring is meant to be driven by patient-reported answers and should align with the person s level of substance-use risk as determined by validated screening and assessment tools. In practice, that means the app is expected to do more than generic reminders. It should take structured inputs from patients, interpret those inputs in the context of established measures, and then respond with feedback that matches the individual s needs and current risk level. The feedback should reinforce self-monitoring and self-management skills and support adherence to the treatment plan or goals established during the clinical intervention.
The announcement also emphasizes that the application should be grounded in evidence-based behavior change approaches commonly used in substance-use care within medical settings. Examples named include motivational interviewing principles and other behavioral therapy concepts. The expectation is that the technology will promote health-supporting behaviors in a way that is consistent with what clinicians would recommend, helping patients translate a brief conversation in primary care into concrete next steps between visits. This can include encouraging reflection on substance use patterns, prompting coping strategies, supporting goal tracking, and helping the patient recognize triggers and progress over time.
Another key feature is tracking and accountability for health action items. The tool is expected to monitor whether patients complete recommended steps such as attending follow-up appointments, engaging in indicated treatment, or completing referrals and linkages to additional services. The overall design goal is to improve coordination and delivery of indicated services for primary care patients who are at risk of developing substance use disorders, meaning the app should function as a practical bridge between screening, brief intervention, and the follow-up care pathway, rather than operating as a standalone wellness product.
From an administrative standpoint, this is a discretionary grant in the health and education activity category under CFDA 93.279, offered by NIH. The eligible applicant pool is limited to small businesses, consistent with the R41/R42 mechanism, which is typically associated with phased small business innovation or technology development efforts where early prototyping and testing are expected. Clinical trial participation is described as optional, indicating applicants may propose studies that include clinical trial elements if appropriate, but they are not strictly required for every project approach.
Eligibility rules explicitly exclude non-U.S. (foreign) institutions from applying, and non-U.S. components of U.S. organizations are also not eligible to apply. However, foreign components may be allowed under NIH policy definitions, which usually means certain project elements can involve foreign collaboration or resources if they meet NIH requirements and are justified, but the applicant organization itself must be an eligible U.S. small business. The funding opportunity was created on 2019-01-09, with an original closing date of 2019-03-19.Apply for RFA DA 19 022
- The National Institutes of Health in the education, health sector is offering a public funding opportunity titled "Mobile Technologies Extending Reach of Primary Care for Substance-Use-Disorders (R41/R42 Clinical Trial Optional)" and is now available to receive applicants.
- Interested and eligible applicants and submit their applications by referencing the CFDA number(s): 93.279.
- This funding opportunity was created on 2019-01-09.
- Applicants must submit their applications by 2019-03-19. (Agency may still review applications by suitable applicants for the remaining/unused allocated funding in 2026.)
- Eligible applicants include: Small businesses.
[Watch] Creating a grant proposal using the step-by-step wizard inside the applicant portal:
Frequently Asked Questions (FAQs)
What is the name of this grant opportunity?
The opportunity is titled Mobile Technologies Extending Reach of Primary Care for Substance-Use-Disorders (R41/R42 Clinical Trial Optional).
What is the Funding Opportunity Number (FON)?
The Funding Opportunity Number is RFA-DA-19-022.
Who is offering this funding opportunity?
This is a National Institutes of Health (NIH) funding opportunity.
What type of grant is this?
It is a discretionary grant in the health and education activity category, using the R41/R42 small business mechanism (commonly used for phased innovation, prototyping, and testing).
What is the CFDA number associated with this opportunity?
The CFDA number listed is 93.279.
What is the main purpose of this grant?
The grant focuses on creating and testing a prototype mobile or tablet application that can be used in U.S. primary care settings to support follow-up care for patients with risky or problematic substance use.
What problem is the funded technology meant to address in primary care?
The goal is to give primary care providers a practical, low-cost, easy-to-use digital tool that helps extend the impact of brief interventions beyond the clinic visit, especially when time, staffing, and access to specialty treatment are limited.
What kind of technology is expected to be developed?
The opportunity emphasizes a mobile or tablet application intended for use in primary care workflows, with a focus on enabling ongoing follow-up support after an intervention for risky substance use.
Is the application meant to be used in the United States or internationally?
The described use case is specifically U.S. primary care settings.
What is a central required function of the application?
A central requirement is that the app delivers timely, tailored feedback to patients after they have received an intervention for risky substance use.
What does "tailored feedback" mean in this opportunity?
Tailoring should be driven by patient-reported answers and aligned with the patient’s substance-use risk level as determined by validated screening and assessment tools. The app is expected to do more than send generic reminders.
How is the patient’s substance-use risk level supposed to be determined?
The risk level is expected to be determined using validated screening and assessment tools, with app feedback aligned to the results of those measures.
What kinds of patient inputs should the app use to generate feedback?
The app is expected to take structured inputs from patients (patient-reported answers), interpret them using established measures, and provide feedback that matches the individual’s needs and current risk level.
What should the tailored feedback help patients do?
The feedback should reinforce self-monitoring and self-management skills and support adherence to the treatment plan or goals established during the clinical intervention.
Does the opportunity describe any evidence-based approaches the app should follow?
Yes. The announcement emphasizes grounding the application in evidence-based behavior change approaches commonly used in substance-use care within medical settings. Examples named include motivational interviewing principles and other behavioral therapy concepts.
What types of behaviors or activities might the app encourage?
Examples described include encouraging reflection on substance use patterns, prompting coping strategies, supporting goal tracking, and helping patients recognize triggers and progress over time.
What role should the app play between primary care visits?
The app is intended to help patients translate a brief conversation in primary care into concrete next steps between visits, extending the impact of clinic-based brief interventions.
Is tracking and accountability expected to be part of the application?
Yes. A key feature is tracking and accountability for health action items.
What kinds of action items should the app track?
The tool is expected to monitor whether patients complete recommended steps such as attending follow-up appointments, engaging in indicated treatment, or completing referrals and linkages to additional services.
What is the overall care pathway focus of this project?
The design goal is to improve coordination and delivery of indicated services for primary care patients at risk of developing substance use disorders, acting as a bridge between screening, brief intervention, and follow-up care, rather than being a standalone wellness product.
Is the application intended to replace specialty treatment?
The opportunity describes the tool as helping when access to specialty treatment is limited and as improving coordination and follow-up. It is framed as a bridge supporting the follow-up pathway, not as a replacement for indicated services.
Who is eligible to apply?
The eligible applicant pool is limited to small businesses, consistent with the R41/R42 mechanism.
Are foreign (non-U.S.) organizations eligible to apply?
No. Eligibility rules explicitly exclude non-U.S. (foreign) institutions from applying.
Can a non-U.S. component of a U.S. organization apply?
No. The opportunity states that non-U.S. components of U.S. organizations are not eligible to apply.
Are any foreign activities allowed at all?
The information provided notes that foreign components may be allowed under NIH policy definitions, meaning certain justified project elements could involve foreign collaboration or resources under NIH requirements, but the applicant organization must be an eligible U.S. small business.
Are clinical trials required?
No. The opportunity is described as Clinical Trial Optional, meaning applicants may propose studies that include clinical trial elements if appropriate, but clinical trials are not required for every project approach.
What development stage does the opportunity emphasize?
It emphasizes creating and testing a prototype, consistent with an early-stage, phased small business innovation/technology development approach.
When was this funding opportunity created?
The opportunity was created on 2019-01-09.
What was the original closing date?
The original closing date listed is 2019-03-19.
Does the opportunity emphasize cost or usability?
Yes. The tool is described as needing to be practical, low-cost, and easy-to-use for primary care providers.
Is generic messaging considered sufficient for this application?
No. The opportunity explicitly indicates the app should do more than generic reminders by using structured patient inputs and validated tools to generate tailored feedback aligned to the patient’s risk level.
Browse more opportunities from the same category: Education, Health
Next opportunity: Kenya Self-Reliance Development Coalition (KSDC)
Previous opportunity: Promoting Research on Music and Health: Fundamentals and Applications (R21 Clinical Trials Optional)
Applicant Portal:
Are you interested in learning about about how to apply for this government funding opportunity? You can create a free applicant account and receive instant access to our applicant portal that many business owners like you have benefited from.
Apply for RFA DA 19 022
Applicants also applied for:
Applicants who have applied for this opportunity (RFA DA 19 022) also looked into and applied for these:
| Funding Opportunity |
|---|
| Mobile Technologies Extending Reach of Primary Care for Substance-Use-Disorders (R43/R44 Clinical Trial Optional) Apply for RFA DA 19 021 Funding Number: RFA DA 19 021 Agency: National Institutes of Health Category: Education, Health Funding Amount: Case Dependent |
| The Experimental Therapeutics Clinical Trials Network (UM1 Clinical Trials Required) Apply for RFA CA 19 007 Funding Number: RFA CA 19 007 Agency: National Institutes of Health Category: Education, Health Funding Amount: $1,250,000 |
| Virtual Reality Tools to Enhance Evidence Based Treatment of Substance Use Disorders (R43/R44 - Clinical Trial Optional) Apply for RFA DA 19 033 Funding Number: RFA DA 19 033 Agency: National Institutes of Health Category: Education, Health Funding Amount: Case Dependent |
| The Experimental Therapeutics Clinical Trials Network (ETCTN) Pharmacokinetic Resource Laboratories (U24 Clinical Trials Not Allowed) Apply for RFA CA 19 008 Funding Number: RFA CA 19 008 Agency: National Institutes of Health Category: Education, Health Funding Amount: $320,000 |
| Improving Outcomes for Pediatric, Adolescent and Young Adult Cancer Survivors (U01 Clinical Trial Required) Apply for RFA CA 19 033 Funding Number: RFA CA 19 033 Agency: National Institutes of Health Category: Education, Health Funding Amount: $500,000 |
| Virtual Reality Tools to Enhance Evidence Based Treatment of Substance Use Disorders (R41/R42 - Clinical Trial Optional) Apply for RFA DA 19 032 Funding Number: RFA DA 19 032 Agency: National Institutes of Health Category: Education, Health Funding Amount: Case Dependent |
| Provocative Questions (PQs) in Cancer with an Underlying HIV Infection (R01 Clinical Trial Optional) Apply for RFA CA 19 032 Funding Number: RFA CA 19 032 Agency: National Institutes of Health Category: Education, Health Funding Amount: Case Dependent |
| HIV/AIDS Adult Therapeutics Clinical Trials Network Leadership and Operations Center (UM1 Clinical Trial Required) Apply for RFA AI 19 003 Funding Number: RFA AI 19 003 Agency: National Institutes of Health Category: Education, Health Funding Amount: Case Dependent |
| Biology of Bladder Cancer (R21 Clinical Trial Optional) Apply for PAR 19 169 Funding Number: PAR 19 169 Agency: National Institutes of Health Category: Education, Health Funding Amount: $200,000 |
| Biology of Bladder Cancer (R01 Clinical Trial Optional) Apply for PAR 19 168 Funding Number: PAR 19 168 Agency: National Institutes of Health Category: Education, Health Funding Amount: Case Dependent |
| Administrative Supplements to NCI Grant and Cooperative Agreement Awards to Support Collaborations with the PDX Development and Trial Centers Research Network (PDXNet) (Admin Supp Clinical Trial Not Allowed) Apply for PA 19 174 Funding Number: PA 19 174 Agency: National Institutes of Health Category: Education, Health Funding Amount: Case Dependent |
| NCI Awardee Skills Development Consortium: Research Education Short Courses (UE5 Clinical Trial Not Allowed) Apply for RFA CA 19 010 Funding Number: RFA CA 19 010 Agency: National Institutes of Health Category: Education, Health Funding Amount: Case Dependent |
| NCI Awardee Skills Development Consortium: Program Logistics and Evaluation Coordinating Center (U24 Clinical Trial Not Allowed) Apply for RFA CA 19 011 Funding Number: RFA CA 19 011 Agency: National Institutes of Health Category: Education, Health Funding Amount: Case Dependent |
| Biology of Bladder Cancer (R21 Clinical Trial Optional) Apply for PAR 19 184 Funding Number: PAR 19 184 Agency: National Institutes of Health Category: Education, Health Funding Amount: $200,000 |
| Biology of Bladder Cancer (R01 Clinical Trial Optional) Apply for PAR 19 183 Funding Number: PAR 19 183 Agency: National Institutes of Health Category: Education, Health Funding Amount: Case Dependent |
| Microbial-based Cancer Therapy -Bugs as Drugs (R21 Clinical Trial Not Allowed) Apply for PAR 19 194 Funding Number: PAR 19 194 Agency: National Institutes of Health Category: Education, Health Funding Amount: $200,000 |
| Ruth L. Kirschstein National Research Service Award (NRSA) Individual Predoctoral Fellowship to Promote Diversity in Health-Related Research (Parent F31) Apply for PA 19 196 Funding Number: PA 19 196 Agency: National Institutes of Health Category: Education, Health Funding Amount: Case Dependent |
| Microbial-based Cancer Therapy -Bugs as Drugs (R01 Clinical Trial Not Allowed) Apply for PAR 19 193 Funding Number: PAR 19 193 Agency: National Institutes of Health Category: Education, Health Funding Amount: Case Dependent |
| Mechanisms Underlying the Contribution of Sleep Disturbances to Pain (R21 Clinical Trial Optional) Apply for PA 19 201 Funding Number: PA 19 201 Agency: National Institutes of Health Category: Education, Health Funding Amount: $200,000 |
| Mechanisms Underlying the Contribution of Sleep Disturbances to Pain (R01 Clinical Trial Optional) Apply for PA 19 200 Funding Number: PA 19 200 Agency: National Institutes of Health Category: Education, Health Funding Amount: Case Dependent |
Grant application guides and resources
It is always free to apply for government grants. However the process may be very complex depending on the funding opportunity you are applying for. Let us help you!
Apply for Grants
Inside Our Applicants Portal
Access Applicants Portal
- Grants Repository - Access current and historic funding opportunities with ease. Thousands of funding opportunities are published every week. We can help you sort through the database and find the eligible ones to apply for.
- Applicant Video Guides - The grant application process can be challenging to follow. We can help you with intuitive video guides to speed up the process and eliminate errors in submissions.
- Grant Proposal Wizard - We have developed a network of private funding organizations and investors across the United States. We can reach out and submit your proposal to these contacts to maximize your chances of getting the funding you need.
Premium leads for funding administrators, grant writers, and loan issuers
Thousands of people visit our website for their funding needs every day. When a user creates a grant proposal and files for submission, we pass the information on to funding administrators, grant writers, and government loan issuers.
If you manage government grant programs, provide grant writing services, or issue personal or government loans, we can help you reach your audience.
Learn More
Request more information:
Would you like to learn more about this funding opportunity, similar opportunities to "RFA DA 19 022", eligibility, application service, and/or application tips? Submit an inquiry below:
Don't forget to subscribe to our grant alerts mailing list to receive weekly alerts on new and updated grant funding opportunities like this one in your email.